Cargando…
A novel individualized strategy for cryoballoon catheter ablation in patients with paroxysmal atrial fibrillation
BACKGROUND: The optimal dosage for cryoablation of atrial fibrillation (Cryo-AF) is still unknown. To evaluate the efficacy of an individualized freeze duration, we compared the clinical outcome of patients treated with a time-to-pulmonary vein isolation (TT-PVI) or temperature-guided ablation proto...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918665/ https://www.ncbi.nlm.nih.gov/pubmed/31847803 http://dx.doi.org/10.1186/s12872-019-01295-1 |
_version_ | 1783480638170464256 |
---|---|
author | Ding, Jun Xu, Jing Ma, Wei Chen, Bingwei Yang, Peigen Qi, Yu Sun, Shan Cheng, Aijuan |
author_facet | Ding, Jun Xu, Jing Ma, Wei Chen, Bingwei Yang, Peigen Qi, Yu Sun, Shan Cheng, Aijuan |
author_sort | Ding, Jun |
collection | PubMed |
description | BACKGROUND: The optimal dosage for cryoablation of atrial fibrillation (Cryo-AF) is still unknown. To evaluate the efficacy of an individualized freeze duration, we compared the clinical outcome of patients treated with a time-to-pulmonary vein isolation (TT-PVI) or temperature-guided ablation protocol to the outcome of patients treated with a conventional ablation protocol. METHODS: A total of 164 consecutive patients were included in the study. One method employed was a conventional dosing protocol (at least 2 applications of 180 s each) (the Cryo-AF(Conventional) group n = 84), and the second method had a shorter protocol that was based on the TT-PVI or achievement of − 40 °C within 60 s (the Cryo-AF(Dosing) group n = 80) RESULTS: We treated 656 pulmonary veins (PVs) with 1420 cryotherapy applications. The mean number of applications per patient was 8.7 ± 0.8, with no difference between groups (Cryo-AF(Conventional), 8.7 ± 0.8 versus Cryo-AF(Dosing),8.6 ± 0.8; P = 0.359). The Cryo-AF(Dosing) group required significantly less total cryotherapy application time (990.60 ± 137.77versus 1501.58 ± 89.60 s; P < 0.001) and left atrial dwell time (69.91 ± 6.91 versus 86.48 ± 7.03 min; P < 0.001) than the Cryo-AF(Conventional) group. Additionally, the Cryo-AF(Dosing) group required significantly less total procedure time (95.03 ± 6.50 versus 112.43 ± 7.11 min; P < 0.001). We observed acute ATP-induced or spontaneous vein electric reconnections in 13 veins (1.98%) after 20 min. The reconnection rates between the Cryo-AF(Conventional) and Cryo-AF(Dosing) groups were similar in that 2.98 and 0.94% of the initially isolated veins were reconnected, respectively, (P = 0.061). There was no difference in the recurrence rate of free atrial arrhythmia after a 1-year follow-up, which were 78.75% in the Cryo-AF(Dosing) group versus 78.57% in the Cryo-AF(Conventional) group (P = 0.978). CONCLUSION: A novel Cryo-AF dosing protocol guided by temperature or the TT-PVI can be used to individualize an ablation strategy. This new protocol can lead to a significant reduction in duration of the procedure, the cryoenergy dosage and the left atrial dwell time. The procedure had equal safety and similar acute and 1-year follow-up outcomes compared to the conventional approach. |
format | Online Article Text |
id | pubmed-6918665 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-69186652019-12-20 A novel individualized strategy for cryoballoon catheter ablation in patients with paroxysmal atrial fibrillation Ding, Jun Xu, Jing Ma, Wei Chen, Bingwei Yang, Peigen Qi, Yu Sun, Shan Cheng, Aijuan BMC Cardiovasc Disord Research Article BACKGROUND: The optimal dosage for cryoablation of atrial fibrillation (Cryo-AF) is still unknown. To evaluate the efficacy of an individualized freeze duration, we compared the clinical outcome of patients treated with a time-to-pulmonary vein isolation (TT-PVI) or temperature-guided ablation protocol to the outcome of patients treated with a conventional ablation protocol. METHODS: A total of 164 consecutive patients were included in the study. One method employed was a conventional dosing protocol (at least 2 applications of 180 s each) (the Cryo-AF(Conventional) group n = 84), and the second method had a shorter protocol that was based on the TT-PVI or achievement of − 40 °C within 60 s (the Cryo-AF(Dosing) group n = 80) RESULTS: We treated 656 pulmonary veins (PVs) with 1420 cryotherapy applications. The mean number of applications per patient was 8.7 ± 0.8, with no difference between groups (Cryo-AF(Conventional), 8.7 ± 0.8 versus Cryo-AF(Dosing),8.6 ± 0.8; P = 0.359). The Cryo-AF(Dosing) group required significantly less total cryotherapy application time (990.60 ± 137.77versus 1501.58 ± 89.60 s; P < 0.001) and left atrial dwell time (69.91 ± 6.91 versus 86.48 ± 7.03 min; P < 0.001) than the Cryo-AF(Conventional) group. Additionally, the Cryo-AF(Dosing) group required significantly less total procedure time (95.03 ± 6.50 versus 112.43 ± 7.11 min; P < 0.001). We observed acute ATP-induced or spontaneous vein electric reconnections in 13 veins (1.98%) after 20 min. The reconnection rates between the Cryo-AF(Conventional) and Cryo-AF(Dosing) groups were similar in that 2.98 and 0.94% of the initially isolated veins were reconnected, respectively, (P = 0.061). There was no difference in the recurrence rate of free atrial arrhythmia after a 1-year follow-up, which were 78.75% in the Cryo-AF(Dosing) group versus 78.57% in the Cryo-AF(Conventional) group (P = 0.978). CONCLUSION: A novel Cryo-AF dosing protocol guided by temperature or the TT-PVI can be used to individualize an ablation strategy. This new protocol can lead to a significant reduction in duration of the procedure, the cryoenergy dosage and the left atrial dwell time. The procedure had equal safety and similar acute and 1-year follow-up outcomes compared to the conventional approach. BioMed Central 2019-12-17 /pmc/articles/PMC6918665/ /pubmed/31847803 http://dx.doi.org/10.1186/s12872-019-01295-1 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Ding, Jun Xu, Jing Ma, Wei Chen, Bingwei Yang, Peigen Qi, Yu Sun, Shan Cheng, Aijuan A novel individualized strategy for cryoballoon catheter ablation in patients with paroxysmal atrial fibrillation |
title | A novel individualized strategy for cryoballoon catheter ablation in patients with paroxysmal atrial fibrillation |
title_full | A novel individualized strategy for cryoballoon catheter ablation in patients with paroxysmal atrial fibrillation |
title_fullStr | A novel individualized strategy for cryoballoon catheter ablation in patients with paroxysmal atrial fibrillation |
title_full_unstemmed | A novel individualized strategy for cryoballoon catheter ablation in patients with paroxysmal atrial fibrillation |
title_short | A novel individualized strategy for cryoballoon catheter ablation in patients with paroxysmal atrial fibrillation |
title_sort | novel individualized strategy for cryoballoon catheter ablation in patients with paroxysmal atrial fibrillation |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918665/ https://www.ncbi.nlm.nih.gov/pubmed/31847803 http://dx.doi.org/10.1186/s12872-019-01295-1 |
work_keys_str_mv | AT dingjun anovelindividualizedstrategyforcryoballooncatheterablationinpatientswithparoxysmalatrialfibrillation AT xujing anovelindividualizedstrategyforcryoballooncatheterablationinpatientswithparoxysmalatrialfibrillation AT mawei anovelindividualizedstrategyforcryoballooncatheterablationinpatientswithparoxysmalatrialfibrillation AT chenbingwei anovelindividualizedstrategyforcryoballooncatheterablationinpatientswithparoxysmalatrialfibrillation AT yangpeigen anovelindividualizedstrategyforcryoballooncatheterablationinpatientswithparoxysmalatrialfibrillation AT qiyu anovelindividualizedstrategyforcryoballooncatheterablationinpatientswithparoxysmalatrialfibrillation AT sunshan anovelindividualizedstrategyforcryoballooncatheterablationinpatientswithparoxysmalatrialfibrillation AT chengaijuan anovelindividualizedstrategyforcryoballooncatheterablationinpatientswithparoxysmalatrialfibrillation AT dingjun novelindividualizedstrategyforcryoballooncatheterablationinpatientswithparoxysmalatrialfibrillation AT xujing novelindividualizedstrategyforcryoballooncatheterablationinpatientswithparoxysmalatrialfibrillation AT mawei novelindividualizedstrategyforcryoballooncatheterablationinpatientswithparoxysmalatrialfibrillation AT chenbingwei novelindividualizedstrategyforcryoballooncatheterablationinpatientswithparoxysmalatrialfibrillation AT yangpeigen novelindividualizedstrategyforcryoballooncatheterablationinpatientswithparoxysmalatrialfibrillation AT qiyu novelindividualizedstrategyforcryoballooncatheterablationinpatientswithparoxysmalatrialfibrillation AT sunshan novelindividualizedstrategyforcryoballooncatheterablationinpatientswithparoxysmalatrialfibrillation AT chengaijuan novelindividualizedstrategyforcryoballooncatheterablationinpatientswithparoxysmalatrialfibrillation |